Patrick Plesiat

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1140092/publications.pdf

Version: 2024-02-01

130 papers	7,883 citations	57758 44 h-index	54911 84 g-index
133 all docs	133 docs citations	133 times ranked	8326 citing authors

#	Article	IF	Citations
1	Serological biomarkers for the diagnosis of Mycobacterium abscessus infections in cystic fibrosis patients. Journal of Cystic Fibrosis, 2022, 21, 353-360.	0.7	6
2	Genomic analysis of CTX-M-115 and OXA-23/-72 co-producing Acinetobacter baumannii, and their potential to spread resistance genes by natural transformation. Journal of Antimicrobial Chemotherapy, 2022, 77, 1542-1552.	3.0	4
3	IgA Serological Response for the Diagnosis of Mycobacterium abscessus Infections in Patients with Cystic Fibrosis. Microbiology Spectrum, 2022, 10, e0019222.	3.0	3
4	Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	35
5	Reassessment of the cooperativity between efflux system MexAB-OprM and cephalosporinase AmpC in the resistance of Pseudomonas aeruginosa to Î²-lactams. Journal of Antimicrobial Chemotherapy, 2021, 76, 536-539.	3.0	6
6	Involvement of the Pseudomonas aeruginosa MexABâ€“OprM efflux pump in the secretion of the metallophore pseudopaline. Molecular Microbiology, 2021, 115, 84-98.	2.5	16
7	Targeted Genome Reduction of Pseudomonas aeruginosa Strain PAO1 Led to the Development of Hypovirulent and Hypersusceptible rDNA Hosts. Frontiers in Bioengineering and Biotechnology, 2021, 9, 640450.	4.1	4
8	1,2,3-Triazole-gold(I)-triethylposphine derivatives active against resistant Gram-positive pathogens. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127879.	2.2	3
9	Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing ofPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2021, 76, 2586-2592.	3.0	11
10	Negative Impact of Citral on Susceptibility of Pseudomonas aeruginosa to Antibiotics. Frontiers in Microbiology, 2021, 12, 709838.	3.5	3
11	Detection of Colistin Resistance in Pseudomonas aeruginosa Using the MALDIxin Test on the Routine MALDI Biotyper Sirius Mass Spectrometer. Frontiers in Microbiology, 2021, 12, 725383.	3.5	12
12	Molecular and epidemiological investigation of a colistin-resistant OXA-23-/NDM-1-producing Acinetobacter baumannii outbreak in the Southwest Indian Ocean Area. International Journal of Antimicrobial Agents, 2021, 58, 106402.	2.5	8
13	An unusual community-acquired invasive and multi systemic infection due to ExoU-harboring Pseudomonas aeruginosa strain: Clinical disease and microbiological characteristics. Journal of Microbiology, Immunology and Infection, 2020, 53, 647-651.	3.1	8
14	A Standard Numbering Scheme for Class C Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	50
15	Coordinate overexpression of two <scp>RND</scp> efflux systems, <scp>ParXY</scp> and <scp>TtgABC</scp>, is responsible for multidrug resistance in Pseudomonas putida. Environmental Microbiology, 2020, 22, 5222-5231.	3.8	4
16	Infective Endocarditis Related to Unusual Microorganisms: A Prospective Population-Based Study. Open Forum Infectious Diseases, 2020, 7, ofaa127.	0.9	8
17	Beta-Hemolytic Streptococcal Infective Endocarditis: Characteristics and Outcomes From a Large, Multinational Cohort. Open Forum Infectious Diseases, 2020, 7, ofaa120.	0.9	12
18	Improvement of a disk diffusion method for antibiotic susceptibility testing of anaerobic bacteria. French recommendations revisited for 2020. Anaerobe, 2020, 64, 102213.	2.1	13

#	Article	IF	Citations
19	Chryso-lactams:Gold(I) derivatives of ampicillin with specific activity against Gram-positive pathogens. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127098.	2.2	9
20	The Efflux Pump MexXY/OprM Contributes to the Tolerance and Acquired Resistance of Pseudomonas aeruginosa to Colistin. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	32
21	Production of Norspermidine Contributes to Aminoglycoside Resistance in pmrAB Mutants of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	18
22	Cinnamaldehyde Induces Expression of Efflux Pumps and Multidrug Resistance in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	24
23	Evaluation of the Immunochromatographic NG-Test Carba 5 for Rapid Identification of Carbapenemase in Nonfermenters. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	23
24	Acquisition of Class C Î²-Lactamase PAC-1 by Sequence Type 644 Strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
25	Sequential emergence of colistin and rifampicin resistance in an OXA-72- producing outbreak strain of Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2019, 53, 669-673.	2.5	9
26	ISAba1-dependent overexpression of eptA in clinical strains of Acinetobacter baumannii resistant to colistin. Journal of Antimicrobial Chemotherapy, 2019, 74, 2544-2550.	3.0	19
27	Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137. Journal of Cystic Fibrosis, 2019, 18, 804-807.	0.7	20
28	Carbapenem-Susceptible OXA-23-Producing Proteus mirabilis in the French Community. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	10
29	Identification of Diverse Integron and Plasmid Structures Carrying a Novel Carbapenemase Among Pseudomonas Species. Frontiers in Microbiology, 2019, 10, 404.	3.5	19
30	The Transcriptional Repressor SmvR Is Important for Decreased Chlorhexidine Susceptibility in Enterobacter cloacae Complex. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	7
31	A case of leech-associated infection involving an extended-spectrum Î²-lactamase-producing and extensively drug-resistant Aeromonas hydrophila. Clinical Microbiology and Infection, 2019, 25, 394-395.	6.0	4
32	A novel IncQ plasmid carrying geneblaCTX-M-3 inPseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2019, 74, 823-825.	3.0	5
33	Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry. PLoS ONE, 2019, 14, e0210201.	2.5	11
34	In vitro activities of a new fluoroquinolone derivative highly active against Chlamydia trachomatis. Bioorganic Chemistry, 2019, 83, 180-185.	4.1	10
35	Emergence of plasmid-mediated colistin resistance (mcr-1) among Enterobacteriaceae strains: Laboratory detection of resistance and measures to control its dissemination. MÃ©decine Et Maladies Infectieuses, 2018, 48, 250-255.	5.0	3
36	Constitutive Activation of MexT by Amino Acid Substitutions Results in MexEF-OprN Overproduction in Clinical Isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	23

#	Article	IF	Citations
37	Mutations in Gene fusA1 as a Novel Mechanism of Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	61
38	Rapid detection of colistin resistance in Acinetobacter baumannii using MALDI-TOF-based lipidomics on intact bacteria. Scientific Reports, 2018, 8, 16910.	3.3	61
39	Higher Prevalence of PldA, a Pseudomonas aeruginosa Trans-Kingdom H2-Type VI Secretion System Effector, in Clinical Isolates Responsible for Acute Infections and in Multidrug Resistant Strains. Frontiers in Microbiology, 2018, 9, 2578.	3.5	22
40	Rapid detection and discrimination of chromosome- and MCR-plasmid-mediated resistance to polymyxins by MALDI-TOF MS in Escherichia coli: the MALDIxin test. Journal of Antimicrobial Chemotherapy, 2018, 73, 3359-3367.	3.0	66
41	Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic. Scientific Reports, 2017, 7, 40208.	3.3	34
42	Resistance to polymyxins in Gram-negative organisms. International Journal of Antimicrobial Agents, 2017, 49, 526-535.	2.5	301
43	Unexpected persistence of extended-spectrum Î²-lactamase-producing Enterobacteriaceae in the faecal microbiota of hospitalised patients treated with imipenem. International Journal of Antimicrobial Agents, 2017, 50, 81-87.	2.5	23
44	Predominance of healthcare-associated cases among episodes of community-onset bacteraemia due to extended-spectrum Î²-lactamase-producing Enterobacteriaceae. International Journal of Antimicrobial Agents, 2017, 49, 67-73.	2.5	24
45	Toxic Electrophiles Induce Expression of the Multidrug Efflux Pump MexEF-OprN in Pseudomonas aeruginosa through a Novel Transcriptional Regulator, CmrA. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	35
46	Acquired resistance to macrolides inPseudomonas aeruginosafrom cystic fibrosis patients. European Respiratory Journal, 2017, 49, 1601847.	6.7	42
47	First Detection of GES-5 Carbapenemase-ProducingAcinetobacter baumanniiIsolate. Microbial Drug Resistance, 2017, 23, 556-562.	2.0	36
48	A case of multiple contamination with methylase ArmA-producing pathogens. Journal of Antimicrobial Chemotherapy, 2017, 72, 618-620.	3.0	7
49	Resistance of Animal Strains of Pseudomonas aeruginosa to Carbapenems. Frontiers in Microbiology, 2017, 8, 1847.	3.5	44
50	Diversity of Molecular Mechanisms Conferring Carbapenem Resistance toPseudomonas aeruginosaIsolates from Saudi Arabia. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-7.	1.9	27
51	Pyomelaninâ€producing Pseudomonas aeruginosa selected during chronic infections have a large chromosomal deletion which confers resistance to pyocins. Environmental Microbiology, 2016, 18, 3482-3493.	3.8	57
52	Validated Risk Score for Predicting 6â€Month Mortality in Infective Endocarditis. Journal of the American Heart Association, 2016, 5, e003016.	3.7	98
53	Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy, 2016, 60, 7415-7423.	3.2	99
54	Antimicrobial Drug Efflux Pumps in Pseudomonas aeruginosa. , 2016, , 359-400.		14

#	Article	IF	Citations
55	Ã‰pidÃ©miologie de la rÃ©sistance aux Î²-lactamines chez Pseudomonas aeruginosa. Journal Des Anti-infectieux, 2016, 18, 52-63.	0.1	0
56	Amino Acid Substitutions Account for Most MexS Alterations in Clinical nfxC Mutants of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2016, 60, 2302-2310.	3.2	45
57	Increase of efflux-mediated resistance in Pseudomonas aeruginosa during antibiotic treatment in patients suffering from nosocomial pneumonia. International Journal of Antimicrobial Agents, 2016, 47, 77-83.	2.5	20
58	Prospective evaluation of an algorithm for the phenotypic screening of carbapenemase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2016, 71, 135-140.	3.0	34
59	Development of a Multiple-Locus Variable-Number Tandem-Repeat Typing Scheme for Genetic Fingerprinting of Burkholderia cenocepacia and Application to Nationwide Epidemiological Analysis. Journal of Clinical Microbiology, 2015, 53, 398-409.	3.9	6
60	Type III Secretion System and Virulence Markers Highlight Similarities and Differences between Human- and Plant-Associated Pseudomonads Related to Pseudomonas fluorescens and P. putida. Applied and Environmental Microbiology, 2015, 81, 2579-2590.	3.1	16
61	Avibactam confers susceptibility to a large proportion of ceftazidime-resistantPseudomonas aeruginosaisolates recovered from cystic fibrosis patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1596-1598.	3.0	27
62	Mutations in Î²-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins. Antimicrobial Agents and Chemotherapy, 2015, 59, 6248-6255.	3.2	187
63	Carbapenem resistance in cystic fibrosis strains of Pseudomonas aeruginosa as a result of amino acid substitutions in porin OprD. International Journal of Antimicrobial Agents, 2015, 45, 529-532.	2.5	39
64	The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria. Clinical Microbiology Reviews, 2015, 28, 337-418.	13.6	1,097
65	Impact of Early Valve Surgery on Outcome of Staphylococcus aureus Prosthetic Valve Infective Endocarditis: Analysis in the International Collaboration of Endocarditisâ€“Prospective Cohort Study. Clinical Infectious Diseases, 2015, 60, 741-749.	5.8	84
66	Multiple Mutations Lead to MexXY-OprM-Dependent Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2014, 58, 221-228.	3.2	93
67	Pseudomonas aeruginosa Genome Evolution in Patients and under the Hospital Environment. Pathogens, 2014, 3, 309-340.	2.8	18
68	Antibiotic Resistance Determinants in a Pseudomonas putida Strain Isolated from a Hospital. PLoS ONE, 2014, 9, e81604.	2.5	86
69	Drug Susceptibility Testing by Dilution Methods. Methods in Molecular Biology, 2014, 1149, 49-58.	0.9	1
70	Difficult-to-detect carbapenem-resistant IMP13-producing P. aeruginosa: experience feedback concerning a cluster of urinary tract infections at a surgical clinic in France. Antimicrobial Resistance and Infection Control, 2013, 2, 12.	4.1	4
71	Alternatives to carbapenems in ESBL-producing Escherichia coli infections. MÃ©decine Et Maladies Infectieuses, 2013, 43, 62-66.	5.0	50
72	Outbreak of metallo-Â-lactamase VIM-2-positive strains of Pseudomonas aeruginosa in the Ivory Coast. Journal of Antimicrobial Chemotherapy, 2013, 68, 2952-2954.	3.0	17

#	Article	IF	Citations
73	A Convenient Method To Screen for Carbapenemase-Producing Pseudomonas aeruginosa. Journal of Clinical Microbiology, 2013, 51, 3846-3848.	3.9	21
74	Diversity of Â-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study. Journal of Antimicrobial Chemotherapy, 2013, 68, 1763-1771.	3.0	59
75	Clonal Dissemination of Pseudomonas aeruginosa Isolates Producing Extended-Spectrum Î²-Lactamase SHV-2a. Journal of Clinical Microbiology, 2013, 51, 673-675.	3.9	4
76	Complexity of resistance mechanisms to imipenem in intensive care unit strains of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2013, 68, 1772-1780.	3.0	78
77	Emergence of Imipenem-Resistant Gram-Negative Bacilli in Intestinal Flora of Intensive Care Patients. Antimicrobial Agents and Chemotherapy, 2013, 57, 1488-1495.	3.2	227
78	IMP-29, a Novel IMP-Type Metallo-Î²-Lactamase in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2012, 56, 2187-2190.	3.2	16
79	Unique Biofilm Signature, Drug Susceptibility and Decreased Virulence in Drosophila through the Pseudomonas aeruginosa Two-Component System PprAB. PLoS Pathogens, 2012, 8, e1003052.	4.7	65
80	Evidence for Induction of Integron-Based Antibiotic Resistance by the SOS Response in a Clinical Setting. PLoS Pathogens, 2012, 8, e1002778.	4.7	109
81	Increased Susceptibility of Pseudomonas aeruginosa to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of oprM and Increased Outer-Membrane Permeability. Clinical Infectious Diseases, 2012, 55, 534-542.	5.8	90
82	Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2012, 67, 771-775.	3.0	16
83	Spread of the blaIMP-13 gene in French Pseudomonas aeruginosa through sequence types ST621, ST308 and ST111. International Journal of Antimicrobial Agents, 2012, 40, 571-573.	2.5	15
84	A Two-Component Regulatory System Interconnects Resistance to Polymyxins, Aminoglycosides, Fluoroquinolones, and Î²-Lactams inPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2011, 55, 1211-1221.	3.2	176
85	Pseudomonas aeruginosa et rÃ©sistance aux antibiotiques. Revue Francophone Des Laboratoires, 2011, 2011, 49-62.	0.0	5
86	Pseudomonas aeruginosa: Une virulence complexe. Revue Francophone Des Laboratoires, 2011, 2011, 73-81.	0.0	4
87	The Pseudomonas aeruginosa opportunistic pathogen and human infections. Environmental Microbiology, 2011, 13, 1655-1665.	3.8	239
88	Strain-Tailored Double-Disk Synergy Test Detects Extended-Spectrum Oxacillinases in Pseudomonas aeruginosa. Journal of Clinical Microbiology, 2011, 49, 2262-2265.	3.9	15
89	Role of the MexEF-OprN Efflux System in Low-Level Resistance of Pseudomonas aeruginosa to Ciprofloxacin. Antimicrobial Agents and Chemotherapy, 2011, 55, 5676-5684.	3.2	98
90	Ceftazidime-hydrolysing Â-lactamase OXA-145 with impaired hydrolysis of penicillins in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2011, 66, 1745-1750.	3.0	19

#	Article	IF	Citations
91	Human Cysteine Cathepsins Are Not Reliable Markers of Infection by Pseudomonas aeruginosa in Cystic Fibrosis. PLoS ONE, 2011, 6, e25577.	2.5	21
92	Molecular epidemiology of multidrug-resistant Pseudomonas aeruginosa in a French university hospital. Journal of Hospital Infection, 2010, 76, 316-319.	2.9	26
93	Detection of a new extended-spectrum oxacillinase in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2010, 65, 364-365.	3.0	20
94	Hospital outbreak of Pseudomonas aeruginosa producing extended-spectrum oxacillinase OXA-19. Journal of Medical Microbiology, 2010, 59, 866-869.	1.8	5
95	Nationwide Investigation of Extended-Spectrum Î²-Lactamases, Metallo-Î²-Lactamases, and Extended-Spectrum Oxacillinases Produced by Ceftazidime-Resistant Pseudomonas aeruginosa Strains in France. Antimicrobial Agents and Chemotherapy, 2010, 54, 3512-3515.	3.2	56
96	Heterogeneous Vancomycinâ€Intermediate Susceptibility Phenotype in Bloodstream Methicillinâ€ResistantStaphylococcus aureusIsolates from an International Cohort of Patients with Infective Endocarditis: Prevalence, Genotype, and Clinical Significance. Journal of Infectious Diseases, 2009, 200, 1355-1366.	4.0	120
97	Microbiological and Epidemiological Features of Clinical Respiratory Isolates of Burkholderia gladioli. Journal of Clinical Microbiology, 2009, 47, 1510-1516.	3.9	48
98	Naturally Occurring Class A ÃŸ-Lactamases from the Burkholderia cepacia Complex. Antimicrobial Agents and Chemotherapy, 2009, 53, 876-882.	3.2	51
99	Efflux Unbalance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2009, 53, 1987-1997.	3.2	91
100	Antibiotic susceptibility and mechanisms of Î²-lactam resistance among clinical strains of PseudomonasÂaeruginosa: First report in Algeria. MÃ©decine Et Maladies Infectieuses, 2008, 38, 187-191.	5.0	16
101	Genotypic Diversity of Coagulase-Negative Staphylococci Causing Endocarditis: a Global Perspective. Journal of Clinical Microbiology, 2008, 46, 1780-1784.	3.9	40
102	Phylogenetic Analysis of Viridans Group Streptococci Causing Endocarditis. Journal of Clinical Microbiology, 2008, 46, 3087-3090.	3.9	28
103	Resistance and Virulence of Pseudomonas aeruginosa Clinical Strains Overproducing the MexCD-OprJ Efflux Pump. Antimicrobial Agents and Chemotherapy, 2008, 52, 2455-2462.	3.2	111
104	Relationship between Antibiotic Use and Incidence of MexXY-OprM Overproducers among Clinical Isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2008, 52, 1173-1175.	3.2	42
105	Cumulative Effects of Several Nonenzymatic Mechanisms on the Resistance of Pseudomonas aeruginosa to Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2007, 51, 1016-1021.	3.2	95
106	MexAB-OprM- and MexXY-Overproducing Mutants Are Very Prevalent among Clinical Strains of Pseudomonas aeruginosa with Reduced Susceptibility to Ticarcillin. Antimicrobial Agents and Chemotherapy, 2007, 51, 1582-1583.	3.2	48
107	Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. Journal of Antimicrobial Chemotherapy, 2007, 59, 1021-1024.	3.0	50
108	Pseudomonas aeruginosa May Accumulate Drug Resistance Mechanisms without Losing Its Ability To Cause Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2007, 51, 3531-3536.	3.2	91

#	Article	IF	Citations
109	Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clinical Microbiology and Infection, 2007, 13, 560-578.	6.0	455
110	Genetic analysis of a multiresistant strain of Pseudomonas aeruginosa producing PER-1 Î²-lactamase. Clinical Microbiology and Infection, 2006, 12, 270-278.	6.0	28
111	In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin. Clinical Microbiology and Infection, 2006, 12, 426-432.	6.0	8
112	Diabetes mellitus and infective endocarditis: the insulin factor in patient morbidity and mortality. European Heart Journal, 2006, 28, 59-64.	2.2	38
113	Involvement of the MexXY-OprM Efflux System in Emergence of Cefepime Resistance in Clinical Strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2006, 50, 1347-1351.	3.2	128
114	Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2005, 55, 518-522.	3.0	31
115	Mutations in PA3574 (nalD) Lead to Increased MexAB-OprM Expression and Multidrug Resistance in Laboratory and Clinical Isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2005, 49, 1782-1786.	3.2	126
116	Induction of the MexXY Efflux Pump in Pseudomonas aeruginosa Is Dependent on Drug-Ribosome Interaction. Journal of Bacteriology, 2005, 187, 5341-5346.	2.2	133
117	Role of the Multidrug Efflux System MexXY in the Emergence of Moderate Resistance to Aminoglycosides among Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2004, 48, 1676-1680.	3.2	126
118	Selection of an Antibiotic-Hypersusceptible Mutant of Pseudomonas aeruginosa : Identification of the GlmR Transcriptional Regulator. Antimicrobial Agents and Chemotherapy, 2004, 48, 843-851.	3.2	25
119	Detection of an IS21 insertion sequence in the mexR gene of Pseudomonas aeruginosa increasing ÃŽÂ²-lactam resistance. FEMS Microbiology Letters, 2004, 230, 143-146.	1.8	49
120	Clinical Strains of Pseudomonas aeruginosa Overproducing MexAB-OprM and MexXY Efflux Pumps Simultaneously. Antimicrobial Agents and Chemotherapy, 2004, 48, 1797-1802.	3.2	226
121	Genetic and Phenotypic Variations of a Resistant Pseudomonas aeruginosa Epidemic Clone. Antimicrobial Agents and Chemotherapy, 2003, 47, 1887-1894.	3.2	85
122	MexXY-OprM Efflux Pump Is Necessary for Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2003, 47, 1371-1375.	3.2	153
123	Genotypic and Phenotypic Analysis of Type III Secretion System in a Cohort ofPseudomonas aeruginosaBacteremia Isolates: Evidence for a Possible Association between O Serotypes andexoGenes. Journal of Infectious Diseases, 2003, 188, 512-518.	4.0	83
124	Cost-effectiveness of urinary dipsticks to screen asymptomatic catheter-associated urinary infections in an intensive care unit. Intensive Care Medicine, 2001, 27, 1842-1847.	8.2	23
125	In Vivo Emergence of Multidrug-Resistant Mutants of Pseudomonas aeruginosa Overexpressing the Active Efflux System MexA-MexB-OprM. Antimicrobial Agents and Chemotherapy, 1999, 43, 287-291.	3.2	248
126	Propagation of TEM- and PSE-Type Î²-Lactamases among Amoxicillin-Resistant Salmonella spp. Isolated in France. Antimicrobial Agents and Chemotherapy, 1999, 43, 2430-2436.	3.2	46

#	Article	IF	Citations
127	Uptake of Pyocin S3 Occurs through the Outer Membrane Ferripyoverdine Type II Receptor of Pseudomonas aeruginosa. Journal of Bacteriology, 1999, 181, 3849-3851.	2.2	61
128	Molecular Analysis of the Replication Elements of the Broad-Host-Range RepA/C Replicon. Plasmid, 1996, 36, 26-35.	1.4	38
129	Outer membranes of Gram-negative bacteria are permeable to steroid probes. Molecular Microbiology, 1992, 6, 1323-1333.	2.5	181
130	Elimination of plasmids from Enterobacteriaceae by 4-quinolone derivatives. Journal of Antimicrobial Chemotherapy, 1986, 18, 667-674.	3.0	34